Rapafusyn Pharmaceuticals
United States
- Baltimore, Maryland
- 25/06/2024
- Series A
- $28,000,000
Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.
- Industry Research Services
- Website https://www.rapafusyn.com/
- LinkedIn https://www.linkedin.com/company/rapafusyn-pharmaceuticals/
Related People
Sean X. HuFounder
United States -
New York, New York
> A leader with a track record of successfully building teams and growing a business;
> A recognized world class thought leader in personalized medicine strategies for both drug and molecular diagnostic product development, commercialization and marketing, as well as corporate level personalized medicine strategies;
> A seasoned strategist for the life science industries (pharmaceutical, diagnostics, biotech and beyond), well experienced in product commercialization / global marketing, portfolio optimization, corporate organizational and growth strategies, licensing and corporate development;
> Unique combination of strategic consulting and hands-on, industry operational experience;
> Educated in both science and business, with a BS in Organic Chemistry, a PhD in Genomics, and an MBA double majored in Strategic and Entrepreneurial Management;
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Jupid | $840,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Manifest OS | $60,000,000 | (May 1, 2026)
Iterative Health | $77,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Illuminant Surgical | $8,400,000 | (May 1, 2026)
BioOrbit | $13,334,811 | (May 1, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)